Comparing Outcomes of Oligometastases Treated with Hypofractionated Image-Guided Radiotherapy (HIGRT) with a Simultaneous Integrated Boost (SIB) Technique versus Metastasis Alone: A Multi-Institutional Analysis
Authors:
- Rachel F. ShenkerRSRachel F. Shenker
- Jeremy G. PriceJPJeremy G. Price
- Corbin D. JacobsCJCorbin D. Jacobs
- Manisha PaltaMPManisha Palta
- Brian G. CzitoBCBrian G. Czito
- Yvonne M. MoweryYMYvonne M. Mowery
- John P. KirkpatrickJKJohn P. Kirkpatrick
- Matthew J. BoyerMBMatthew J. Boyer
- Taofik OyekunleTOTaofik Oyekunle
- Donna NiedzwieckiDNDonna Niedzwiecki
- Haijun SongHSHaijun Song
- Joseph K. SalamaJSJoseph K. Salama
Open Access
Abstract
Purpose: We previously reported on the clinical outcomes of treating oligometastases with radiation using an elective simultaneous integrated boost technique (SIB), delivering higher doses to known metastases and reduced doses to adjacent bone or nodal basins. Here we compare outcomes of oligometastases receiving radiation targeting metastases alone (MA) versus those treated via an SIB. Methods: Oligometastatic patients with ≤5 active metastases treated with either SIB or MA radiation at two institutions from 2013 to 2019 were analyzed retrospectively for treatment-related toxicity, pain control, and recurrence patterns. Tumor metastasis control (TMC) was defined as an absence of progression in the high dose planning target volume (PTV). Marginal recurrence (MR) was defined as recurrence outside the elective PTV but within the adjacent bone or nodal basin. Distant recurrence (DR) was defined as any recurrence that is not within the PTV or surrounding bone or nodal basin. The outcome rates were estimated using the Kaplan–Meier method and compared between the two techniques using the log-rank test. Results: 101 patients were treated via an SIB to 90 sites (58% nodal and 42% osseous) and via MA radiation to 46 sites (22% nodal and 78% osseous). The median follow-up among surviving patients was 24.6 months (range 1.4–71.0). Of the patients treated to MA, the doses ranged from 18 Gy in one fraction (22%) to 50 Gy in 10 fractions (50%). Most patients treated with an SIB received 50 Gy to the treated metastases and 30 Gy to the elective PTV in 10 fractions (88%). No acute grade ≥3 toxicities occurred in either cohort. Late grade ≥3 toxicity occurred in 3 SIB patients (vocal cord paralysis and two vertebral body compression), all related to the high dose PTV and not the elective volume. There was similar crude pain relief between cohorts. The MR-free survival rate at 2 years was 87% (95% CI: 70%, 95%) in the MA group and 98% (95% CI: 87%, 99%) in the SIB group (p = 0.07). The crude TMC was 89% (41/46) in the MA group and 94% (85/90) in the SIB group. There were no significant differences in DR-free survival (65% (95% CI: 55–74%; p = 0.24)), disease-free survival (60% (95% CI: 40–75%; p = 0.40)), or overall survival (88% (95% CI: 73–95%; p = 0.26)), between the MA and SIB cohorts. Conclusion: Both SIB and MA irradiation of oligometastases achieved high rates of TMC and similar pain control, with a trend towards improved MR-free survival for oligometastases treated with an SIB. Further investigation of this technique with prospective trials is warranted.Keywords
This publication has 31 references indexed in Scilit:
- A single-institution study of stereotactic body radiotherapy for patients with unresectable visceral pulmonary or hepatic oligometastasesRadiation Oncology, 2012
- Management of Spinal Metastases From Renal Cell Carcinoma Using Stereotactic Body RadiotherapyInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2010
- Systemic review of the patterns of failure following stereotactic body radiation therapy in early-stage non-small-cell lung cancer: Clinical implicationsRadiotherapy and Oncology, 2010
- Multi-Institutional Phase I/II Trial of Stereotactic Body Radiation Therapy for Lung MetastasesJournal of Clinical Oncology, 2009
- Multi-Institutional Phase I/II Trial of Stereotactic Body Radiation Therapy for Liver MetastasesJournal of Clinical Oncology, 2009
- Descriptive Analysis of Oligometastatic Lesions Treated With Curative-Intent Stereotactic Body RadiotherapyInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2008
- Phase I/II study of stereotactic body radiotherapy for spinal metastasis and its pattern of failureJournal of Neurosurgery: Spine, 2007
- Radiosurgery for Spinal MetastasesSpine, 2007
- Docetaxel-induced lymphopenia in patients with solid tumorsCancer, 2000
- Long-term results of lung metastasectomy: Prognostic analyses based on 5206 casesThe Journal of Thoracic and Cardiovascular Surgery, 1997